






## 2016 Operating Grants Competition Results

Researcher	Project Title	Funding Details
<b><i>Alfieri, Carolina</i></b> Research Center, CHU Sainte-Justine	Efficacy testing of a humanized antibody for prevention of Epstein-Barr virus-associated cancers in pediatric transplant patients	\$119,687/ 2 years
<b><i>Bachvarov, Dimcho</i></b> Centre de recherche, CHU de Québec	Investigating <i>in vivo</i> the role of EMT in epithelial ovarian cancer (EOC) dissemination by modulating LY75 expression and analyzing the molecular mechanisms of LY75-mediated control of EOC cellular phenotype	\$120,000/ 2 years
<b><i>Basik, Mark</i></b> Lady Davis Institute for Medical Research	Elucidating novel mechanisms of drug resistance in triple negative breast cancer	\$120,000/ 2 years
<b><i>Beauchemin, Nicole</i></b> McGill University, Goodman Cancer Research Centre	Genetic control of susceptibility to colon cancer development	\$120,000/ 2 years



## 2016 Operating Grants Competition Results

Researcher	Project Title	Funding Details
<b><i>Bennewith, Kevin</i></b> BC Cancer Agency	CCR5+ regulatory T cells in solid tumour metastasis	\$120,000/ 2 years <i>Funded in partnership with CURE Foundation</i> 
<b><i>Blank, Volker</i></b> Lady Davis Institute for Medical Research	Linking ERBB signaling to MAFF transcription factor function in breast cancer	\$120,000/ 2 years <i>Funded in partnership with Quebec Breast Cancer Foundation</i> 
<b><i>Bratman, Scott</i></b> Princess Margaret Cancer Centre	Non-invasive detection of tumour cell death for adaptive radiotherapy in oropharynx cancer	\$120,000/ 2 years
<b><i>Bremner, Rod</i></b> Lunenfeld Tanenbaum Research Institute	Cooperation between LIN28 and RB in cancer initiation	\$120,000/ 2 years <i>Funded in partnership with the C<sup>17</sup> Council</i> 


## 2016 Operating Grants Competition Results

Researcher	Project Title	Funding Details
<i>Copeland, John</i> University of Ottawa	Role of the formin FMNL2 in metastasis and invasion	\$120,000/ 2 years <i>Funded in partnership with the University of Ottawa</i>  uOttawa L'Université canadienne Canada's university
<i>Côté, Jean-François</i> Institut de recherches cliniques de Montréal (IRCM)	Defining the contribution of the microtubule + TIP-binding protein ACF7 toward breast cancer progression	\$120,000/ 2 years <i>Funded in partnership with the Rina Primeau Memorial Fund</i>  Rina Primeau Memorial Fund
<i>Cowan, Kyle</i> CHEO Research Institute, University of Ottawa	Pannexin1 as a new therapeutic target for rhabdomyosarcomas	\$120,000/ 2 years

## 2016 Operating Grants Competition Results

Researcher	Project Title	Funding Details
<i>Dagnino, Lina</i> Western University	Integrin-linked kinase in nonmelanoma skin carcinoma	\$120,000/ 2 years <i>Funded by the Cancer Research Society's Environment-Cancer Fund™, in partnership with Read for the Cure</i>  
<i>Dick, Fred</i> Western University	Exploiting DNA damage and replication stress to kill osteosarcoma cells	\$120,000/ 2 years
<i>Eaves, Connie</i> BC Cancer Agency	Improved xenograft models of human leukemia for testing new therapeutic approaches	\$120,000/ 2 years
<i>Ferbeyre, Gerardo</i> Université de Montréal	Targeting pancreatic cancer initiating cells with novel metformin derivatives	\$120,000/ 2 years <i>Funded in partnership with the Ganotec / Marc-André Pigeon Memorial Fund</i>  



## 2016 Operating Grants Competition Results

Researcher	Project Title	Funding Details
<i>Fradet-Turcotte, Amélie</i> Université Laval	Discovery and validation of ubiquitin-associated mutations in the DNA-damage response pathway in breast cancer.	\$120,000/ 2 years <i>Funded in partnership with CURE Foundation</i>  FONDATION <b>CURE</b> FOUNDATION cancer du sein breast cancer
<i>Greer, Peter</i> Queen's University	Arpin: A novel regulator of actin branching and directional cell migration as a potential therapeutic target in breast cancer	\$120,000/ 2 years
<i>Guérin, Sylvain</i> Centre de recherche du CHU de Québec	Serotonin receptor HTR2B : mode of regulation and contribution to the tumorigenic and metastatic properties of uveal melanoma	\$118,634/ 2 years
<i>Haibe-Kains, Benjamin</i> Princess Margaret Cancer Centre	Inference of tumor microenvironment interactions as a new drug repurposing strategy in triple-negative breast cancer	\$120,000/ 2 years
<i>Haibe-Kains, Benjamin</i> Princess Margaret Cancer Centre	Rational discovery of synergistic drug combinations in non-small cell lung cancer	\$120,000/ 2 years



## 2016 Operating Grants Competition Results

Researcher	Project Title	Funding Details
<i>Hammond, James</i> University of Alberta	Role of the SLC43A3 nucleobase transporter in the therapeutic activity of 6-mercaptopurine in childhood leukemia	\$119,644/ 2 years
<i>Hoodless, Pamela</i> BC Cancer Agency	The role of APELA in ovarian cancer	\$120,000/ 2 years
<i>Huang, Xi</i> The Research Institute of the Hospital for Sick Children	Targeting potassium channel KCNB2 in high-risk medulloblastoma	\$120,000/ 2 years
<i>Ilangumaran, Subburaj</i> Université de Sherbrooke	Role of SOCS1 in tumor immunogenicity: A new immunotherapy strategy to treat liver cancer	\$120,000/ 2 years
<i>Karsan, Aly</i> BC Cancer Agency	Role of TGF-beta signaling in myeloid malignancy	\$120,000/ 2 years
<i>Kim, Tae-Hee</i> The Research Institute of the Hospital for Sick Children	The Sox family of transcription factors in gastric cancer initiation and progression	\$120,000/ 2 years

## 2016 Operating Grants Competition Results



Researcher	Project Title	Funding Details
<b>Koritzinsky, Marianne</b> Princess Margaret Cancer Centre	The role of peroxiredoxin 4 (PDRX4) as a novel target in pancreatic cancer	\$120,000/ 2 years <i>Funded in partnership with the Rob Lutterman Memorial Fund</i>  <b>Rob Lutterman</b> Memorial Fund
<b>Lesage, Sylvie</b> Centre de recherche de l'Hôpital Maisonneuve-Rosemont	A preclinical study for preventing the occurrence of graft-versus host disease through cell-based immunotherapy	\$120,000/ 2 years
<b>Leyton, Jeff</b> Université de Sherbrooke	Antibody-drug conjugates: effective increase in intracellular accumulation – the next frontier	\$120,000/ 2 years
<b>Li, Qiao</b> University of Ottawa	Examining the therapeutic potential of bexarotene in the treatment of cancer cachexia	\$120,000/ 2 years
<b>Lockwood, William</b> BC Cancer Agency	Dependency on the helicase DDX3X provides a novel strategy for targeted therapy in lung cancer	\$120,000/ 2 years <i>Funded in partnership with the Bergeron-Jetté Foundation</i> 

## 2016 Operating Grants Competition Results

Researcher	Project Title	Funding Details
<p><b>Mai, Sabine</b> CancerCare Manitoba, Research Institute in Oncology and Hematology</p>	Disease progression in myeloma	<p>\$120,000/ 2 years <i>Funded in partnership with CancerCare Manitoba Foundation</i></p>  <p><i>All funds raised stay in Manitoba.</i></p>
<p><b>Massey, Thomas</b> Queen's University</p>	Impact of N-acetyltransferase genetic polymorphisms on bioactivation of dietary heterocyclic aromatic amines in human colon mucosa.	<p>\$119,589/ 2 years <i>Funded by the Cancer Research Society's Environment-Cancer Fund™, in partnership with Read for the Cure</i></p> 
<p><b>McManus, Kirk</b> CancerCare Manitoba, Research Institute in Oncology and Hematology</p>	Exploring and exploiting SOD1 as a synthetic lethal interactor of TP53 in cancer.	<p>\$120,000/ 2 years</p>
<p><b>Möröy, Tarik</b> Institut de recherches cliniques de Montréal (IRCM)</p>	The role of the c-Myc co-factor and BTB/POZ domain transcription factor Miz-1 in NOTCH induced T-ALL	<p>\$120,000/ 2 years</p>



## 2016 Operating Grants Competition Results

Researcher	Project Title	Funding Details
<p><b>Morris, Don</b> University of Calgary</p>	<p>Next generation immune treatment strategies for multiple myeloma: immune modulators in conjunction with oncolytic viral therapy</p>	<p>\$120,000/ 2 years <i>Funded in partnership with Myeloma Canada</i></p>  <p>MYELOMA CANADA MAKING MYELOMA MATTER</p>
<p><b>Mossman, Karen</b> McMaster University</p>	<p>Combining epigenetic therapy with oncolytic virus therapy to target lung cancer</p>	<p>\$120,000/ 2 years <i>Funded in partnership with Marjolaine Bazinet - Michel Caya Research Fund</i></p>  <p>Marjolaine Bazinet-Michel Caya Research Fund</p>
<p><b>Muller, William</b> McGill University, Goodman Cancer Research Centre</p>	<p>The role of an alternative ErbB2 splice isoform in lung and breast cancer progression</p>	<p>\$120,000/ 2 years</p>
<p><b>Nelson, Brad</b> BC Cancer Agency</p>	<p>Unleashing the immune response against T cell-poor ovarian cancers</p>	<p>\$120,000/ 2 years</p>

## 2016 Operating Grants Competition Results

Researcher	Project Title	Funding Details
<b><i>Orthwein, Alexandre</i></b> Lady Davis Institute for Medical Research	Identification of novel targets for the treatment of diffuse large B-cell lymphoma.	\$120,000/ 2 years
<b><i>Ouellette, Rodney</i></b> Atlantic Cancer Research Institute	Urine extracellular vesicle RNA biomarkers for risk stratification and monitoring of prostate cancer	\$119,756/ 2 years
<b><i>Pouliot, Frédéric</i></b> Centre de recherche du CHU de Québec	Development of a urine-based prostate cancer cell bioluminescence imaging nanotechnology for single cell transcriptional characterization	\$120,000/ 2 years
<b><i>Rafei, Moutih</i></b> Université de Montréal	Validating the thymopoiesis-stimulating potential of human interleukin-21	\$120,000/ 2 years <i>Funded in partnership with the Benoit Gagnon Research Fund</i>




**Benoit Gagnon**  
Research Fund




## 2016 Operating Grants Competition Results

Researcher	Project Title	Funding Details
<i>Raynal, Noël</i> Université de Montréal	Epigenetic effects of disulfiram against high-risk pediatric neuroblastoma cells	\$120,000/ 2 years
<i>Reimand, Jüri</i> Ontario Institute for Cancer Research	Genome-wide discovery and interpretation of driver genes and pathways in medulloblastoma	\$120,000/ 2 years
<i>Riabowol, Karl</i> University of Calgary	Epigenetic regulation of the epithelial to mesenchymal transition	\$119,000/ 2 years
<i>Robert, François</i> Institut de recherches cliniques de Montréal (IRCM)	Investigating the role of H2A.Z-mediated cryptic transcription in cancers	\$132,000/ 2 years
<i>Saridakis, Vivian</i> York University	Identification of novel USP7-CTD binding proteins and regulation of catalytic activity	\$120,000/ 2 years



## 2016 Operating Grants Competition Results

Researcher	Project Title	Funding Details
<b>Sarret, Philippe</b> Université de Sherbrooke	Developing a pharmaco-genic cancer treatment using Max b HLH LZ as antiproliferative agents and interfering RNA delivery vectors	\$120,000/ 2 years
<b>Schirmacher, Ralf</b> University of Alberta	<i>In vivo</i> imaging of Trk status in cancer for therapeutic outcome prediction with positron emission tomography (PET) and assessing brain penetration of clinical therapeutic Trk candidates	\$119,400/ 2 years <i>Funded in partnership with the C<sup>17</sup> Council</i> 
<b>Servant, Marc</b> Université de Montréal	Role of the de-ubiquitylating enzyme USP17 in colorectal cancer	\$120,000/ 2 years




## 2016 Operating Grants Competition Results

Researcher	Project Title	Funding Details
<b><i>Sleiman, Hanadi</i></b> McGill University	Synergistic chemosensitization of HER2-positive breast cancer cells by a three-pronged strategy integrated within DNA nanostructures.	\$118,000/ 2 years <i>Funded in partnership with the Breast Cancer Society Of Canada</i>  BREAST CANCER SOCIETY <i>of Canada</i> <sup>™</sup> LA SOCIÉTÉ DU CANCER DU SEIN <i>du Canada</i> <sup>™</sup>
<b><i>Sylvestre, Marie-Pierre</i></b> University of Montreal Hospital Research Centre (CRCHUM)	Lifecourse approach to study the development of lifestyle risk factors for cancer	\$120,000/ 2 years <i>Funded by the Cancer Research Society's Environment-Cancer Fund™, in partnership with Read for the Cure</i>  Environment-Cancer Fund™  READ FOR THE CURE
<b><i>Tang, Damu</i></b> McMaster University	Contactin 1 (CNTN1) contributes to the development of castration resistant prostate cancer (CRPC)	\$120,000/ 2 years

## 2016 Operating Grants Competition Results

Researcher	Project Title	Funding Details
<p><b><i>Tonin, Patricia</i></b> The Research Institute of the McGill University Health Centre</p>	<p>FANCI: Investigation of an emerging ovarian cancer susceptibility gene</p>	<p>\$120,000/ 2 years <i>Funded in partnership with Ovarian Cancer Canada</i></p>  <p>Ovarian Cancer Canada Cancer de l'ovaire Canada</p>
<p><b><i>Tremblay, Michel L.</i></b> McGill University, Goodman Cancer Research Centre</p>	<p>Lessons from PTP-PEST interactome: towards novel therapeutic approaches for pancreatic cancer</p>	<p>\$120,000/ 2 years <i>Funded in partnership with the Jean Doré Research Fund</i></p>  <p>Jean Doré Research Fund</p>
<p><b><i>Turcotte, Simon</i></b> University of Montreal Hospital Research Centre (CRCHUM)</p>	<p>Overcoming resistance to T cell-based immunotherapy by elucidating mechanisms driving immune-suppression in the microenvironment of colorectal cancer liver metastases</p>	<p>\$120,000/ 2 years</p>

## 2016 Operating Grants Competition Results

Researcher	Project Title	Funding Details
<b>Verchere, Cameron Bruce</b> University of British Columbia	Diabetes and pancreatic cancer: a role for IAPP?	\$120,000/ 2 years <i>Funded in partnership with the Charlotte Légaré Memorial Fund</i>   <b>Charlotte Légaré</b> Memorial Fund
<b>White, John H.</b> McGill University	Regulation of tumor suppressor and E3 ligase FBW7 by the hormone-bound vitamin D receptor	\$110,400/ 2 years <i>Funded by the Cancer Research Society's Environment-Cancer Fund™, in partnership with Read for the Cure</i>  
<b>Wilson, Michael</b> The Research Institute of the Hospital for Sick Children	Dissecting the functional significance of topoisomerase II beta in leukemia	\$120,000/ 2 years <i>Funded in partnership with the Isaiah 40:31 Memorial Fund</i>   <b>Isaiah 40:31</b> Memorial Fund